3017.0: Monday, November 13, 2000 - 1:30 PM

Abstract #6770

Hepatitis B vaccination for injecting drug users (IDUs): A public health opportunity

Theresa E. Perlis, PhD1, Samuel R. Friedman, PhD1, Don C. Des Jarlais, PhD1, Russell Rockwell, PhD1, Ian Williams, PhD2, and Edgar Monterroso, MD2. (1) National Development and Research Institutes, Inc, Two World Trade Center, 16th floor, New York, NY 10048, (212)845-4484, theresa.perlis@ndri.org, (2) The Centers for Disease Control & Prevention, Atlanta, GA

Objective: To examine HBV vaccination opportunities among IDUs.

Methods: 274 IDUs (primarily under age 30 or injecting for £ 6 years; none knowingly HIV positive), were recruited in 1998-99 through targeted outreach in New York City, and interviewed on hepatitis awareness and prior vaccination. Next they were counseled about hepatitis B and offered testing (anti-HBc, HbsAg, and anti-HBs).

Results: 20% of subjects were completely unaware of hepatitis B prior to interview. Only one subject refused testing. For 62% of subjects, this study provided their first HBV test. Serological evidence of HBV exposure was detected in 78 (29%) and of putative vaccination (anti-HBs alone) in 35 (13%). 160 (59%) tested negative on all markers.

Among the 160 HBV-negatives, 13% reported prior 3-dose vaccination, 7% reported incomplete series, 12% were unsure about prior vaccination. 78% of the "never -vaccinated" said they would accept vaccination if offered. Recency of medical care and HBV awareness were significant (p<.05) independent predictors of potential acceptance.

Among the 35 putative vaccinees, 37% reported receiving the 3-dose series, 11% reported incomplete series, 40% reported no prior vaccination, 11% were unsure.

Conclusion: A sizeable proportion of IDUs remain uninformed about Hepatitis B or appear confused about whether or not they have been vaccinated. Virtually all IDUs are willing to be tested after informative counseling, and a large majority of HBV-susceptible IDUs would willingly accept vaccination. Proactive outreach to increase HBV awareness, and HBV screening followed by vaccination (where appropriate) and effective post-test counseling should be universally accessible to IDUs

Learning Objectives: At the conclusion of the session the participant will understand a) that many injecting drug users could benefit from HBV vaccination; and b) that almost all eligible IDUs would be willing to be vaccinated

Keywords: Injection Drug Users, Hepatitis B

Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: None
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.

The 128th Annual Meeting of APHA